Navigation Links
Regeneron's Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Date:10/27/2009

. In the pivotal clinical development program, patients treated with rilonacept reported a greater improvement in overall symptom scores than patients treated with placebo. These improvements were sustained over time with continued rilonacept treatment. Patients reported their symptoms using a validated daily diary instrument. These assessments represent a critical measure of effectiveness in a disease characterized by frequent, unpredictable symptom flares of variable severity and duration. Unlike other agents used in the treatment of CAPS, rilonacept is supported by patient-reported symptoms data using a validated assessment instrument.

Rilonacept has been developed as a once-weekly injection which can be administered at home by the patient or their care giver following appropriate training. The most commonly reported adverse reactions with rilonacept were injection-site reaction and upper respiratory tract infection. IL-1 blockade may interfere with immune response to infections and treatment should not be initiated in patients with active or chronic infections. There have been reports of serious, life-threatening infections in patients taking rilonacept. Rilonacept should be discontinued if a patient develops a serious infection.

The authorization for approval of rilonacept in the E.U. under exceptional circumstances is permissible for products for which a company can demonstrate that comprehensive data cannot be provided, for example because of the rarity of the condition. Each year, Regeneron will need to provide the EMEA with any new information that may become available for review.

About Cryopyrin-Associated Periodic Syndromes (CAPS)

Recently, medical researchers have identified and described a group of rare, inherited, auto-inflammatory disorders, known as Cryopyrin-Associated Periodic Syndromes or CAPS. Three related conditions make up the broader disease known as CAPS: Familial Cold Aut
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Celsis IVT Granted U.S. Patent for LiverPool(TM) Hepatocytes
2. Peripheral Artery Disease (PAD) Patent Granted to Dimera
3. Sundia and 2 Other CRO Companies Granted Express Customs Clearance Privilege in Shanghai
4. Delcath Systems Granted Third Orphan Drug Designation
5. Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Childrens Hospital Boston and Massachusetts General Hospital
6. FDA has Granted HUD (Humanitarian Use Device) Designation to ITGIs Pericardium Covered Stents, Over and Under(R) and Aneugraft(R), for Treatment of Perforations and Dissections of Native Coronary Arteries and Saphenous Vein Grafts
7. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
8. Tolera Therapeutics Granted Orphan Drug Designation for Organ Transplant Rejection Drug
9. VIASPACE Granted US Patent
10. Crisis Exemption Granted to Market Avipel(R) Corn Seed Treatment in Louisiana
11. Valdoxan(R) Granted Marketing Authorisation for the Treatment of Major Depressive Episodes in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Senior supply chain management executives from over 50 ... of “Reducing Cost, Lead Time, & Defects in the ... the partnership of the Bio Supply Management Alliance ( ... SCMI) of the University of San Diego in ... Institute of Peace and Justice in San Diego, Devendra ...
(Date:7/10/2014)... , July 10, 2014 On ... Dmitry Medvedev , presented Russia,s ... BIOCAD . The Company is developing a unique project ... project BIOCAD develops a number of innovative drugs based ... diseases. The ceremony took place at the International Exhibition ...
(Date:7/10/2014)... July 10, 2014 /PRNewswire-iReach/ -- Tute Genomics, ... today announced an agreement with Lineagen, Inc., ... Lineagen,s NextStep Dx PLUS.  Lineagen, focused ... neurological disorders, currently offers FirstStep Dx ... service used by healthcare providers as a ...
(Date:7/10/2014)... Calif., July 10, 2014   Ceres, Inc . ... seed company, announced today financial results for the three ... on its business. Ceres reported that the ... product performance this growing season in Brazil, which concluded ... the company,s sorghum evaluation areas for part of the ...
Breaking Biology Technology:Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9
... in Nature Physics , they used graphene, the world,s ... Graphene is a sheet of carbon atoms arranged in a ... signs of the conventional magnetism usually associated with such materials ... Manchester researchers the Nobel Prize in Physics in 2010. ...
... LONDON, January 6, 2012 The Lancet ... its first app for iPad is now available on the ... app that makes it easier for healthcare professionals (HCPs) to find ... their iPad. , ,"In this new mobile and tablet age, ...
... company developing a revolutionary non-invasive test for the early ... that it has achieved full automation of its Cell-CT™ ... biosignatures from intact cells.  Development of the fully automated ... $2.6 million grant from the National Institutes of Health,s ...
Cached Biology Technology:Graphene reveals its magnetic personality 2The Lancet Makes Research More Accessible for Healthcare Professionals With New App for iPad 2VisionGate Uses $2.6 Million NIH Grant to Achieve Full Automation of Cell-CT™ 3D Imaging System for Early Diagnosis of Cancer 2VisionGate Uses $2.6 Million NIH Grant to Achieve Full Automation of Cell-CT™ 3D Imaging System for Early Diagnosis of Cancer 3VisionGate Uses $2.6 Million NIH Grant to Achieve Full Automation of Cell-CT™ 3D Imaging System for Early Diagnosis of Cancer 4
(Date:7/11/2014)... In addition to the hippocampus, the marginal division ... and memory. What is the impact degree of ... learning and memory function? Yan Yu and his ... China found, using immunofluorescence staining, that substance P ... hippocampus and striatal marginal division of normal rats. ...
(Date:7/11/2014)... let nerve cells send out electrical signals, Johns Hopkins ... that may offer a new way to protect crops ... way. , Their findingthat naturally occurring insect toxins ... a closely related onesuggests that insecticides can be designed ... bees. A summary of the research, led by Frank ...
(Date:7/10/2014)... NEW YORK , June 27, 2014 /PRNewswire/ ... against Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: ... action, filed in United States District Court, Middle ... Division, is on behalf of a class consisting ... otherwise acquired Provectus securities between December 17, 2013 ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... the Entomological Society of America (ESA) features the Linnaean ... a lively question-and-answer, college bowl-style competition on insect facts ... and entertaining component of the ESA Annual Meeting. ... Branches will compete in the national competition this December ...
... Largo, Fla. April 27, 2009 A new study ... for reattaching large sponges that have been dislodged from coral ... of other large sponge species removed by human activities or ... sponge were removed and reattached at Conch Reef off of ...
... 27, 2009) In an in vitro study, led by ... discovered how a protein called SUMO (Small Ubiquitin-related Modifier) ... chromatin to regulate expression of genes. Chromatin is a ... chromosomes. The interaction between SUMO and the enzyme complex ...
Cached Biology News:Entomological Society of America's Linnaean Games teams selected 2Large sponges may be reattached to coral reefs 2SUMO protein guides chromatin remodeler to suppress genes 2
...
... XL provides RS232/Serial data collection and automation ... Complete instrument integration with Microsoft Excel ... balances, pH meters, titrators, density meters, force ... and serial instruments can be added and ...
DNA sequencing - plasmids or PCR fragments, 3-7 working days service....
Nuclear/Cytosol Fractionation Kit Research Focus: other Storage Temperature: 4C Shipping Temperature: 4C...
Biology Products: